2001PubMedRequires access

The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer.

G Schulze

Open publisher page 53 citations

Abstract

The present study is designed to evaluate the use of the tumor marker Tumor M2-PK in the discrimination between gastrointestinal (Gl) cancer patients and patients with non malignant gastrointestinal diseases. The concentration of Tumor M2-PK was analyzed in EDTA-plasma of 413 Gl cancer-patients and 141 patients with non-malignant diseases. The test resulted in a highly significant discrimination (p < 0.001) of tumor patients and controls. The diagnostic specificity was 89%. A diagnostic sensitivity between 48% and 73%, depending on the different tumor entities (colorectal cancer, gastric cancer, oesophageal cancer and pancreatic cancer), was observed. These sensitivities were generally higher when compared with those of the established tumor markers CEA, CA 19-9 and CA 72-4, with the exception of CA 19-9 in pancreatic cancer. A combination of Tumor M2-PK with the appropriate first choice-marker (e.g. CEA + Tumor M2-PK for colorectal cancer) resulted in a remarkable increase in the sensitivities.

About this research paper

What this paper is about

The present study is designed to evaluate the use of the tumor marker Tumor M2-PK in the discrimination between gastrointestinal (Gl) cancer patients and patients with non malignant gastrointestinal diseases. The concentration of Tumor M2-PK was analyzed in EDTA-plasma of 413 Gl cancer-patients and 141 patients with non-malignant diseases. The test resulted in a highly significant discrimination (p < 0.001) of tumor patients and controls. The diagnostic specificity was 89%. A diagnostic sensitivity between 48% and 73%, depending on the different tumor entities (colorectal cancer, gastric cancer, oesophageal cancer and pancreatic cancer), was observed. These sensitivities were generally higher when compared with those of the established tumor markers CEA, CA 19-9 and CA 72-4, with the exception of CA 19-9 in pancreatic cancer. A combination of Tumor M2-PK with the appropriate first choice-marker (e.g. CEA + Tumor M2-PK for colorectal cancer) resulted in a remarkable increase in the sensitivities.

Why it matters

OpenAlex reports 53 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The present study is designed to evaluate the use of the tumor marker Tumor M2-PK in the discrimination between gastrointestinal (Gl) cancer patients and patients with non malignant gastrointestinal diseases. The concentration of Tumor M2-PK was analyzed in EDTA-plasma of 413 Gl cancer-patients and 141 patients with non-malignant diseases. The test resulted in a highly significant discrimination (p < 0.001) of tumor patients and controls. The diagnostic specificity was 89%. A diagnostic sensitivity between 48% and 73%, depending on the different tumor entities (colorectal cancer, gastric cancer, oesophageal cancer and pancreatic cancer), was observed. These sensitivities were generally higher when compared with those of the established tumor markers CEA, CA 19-9 and CA 72-4, with the exception of CA 19-9 in pancreatic cancer. A combination of Tumor M2-PK with the appropriate first choice-marker (e.g. CEA + Tumor M2-PK for colorectal cancer) resulted in a remarkable increase in the sensitivities.

Key concepts: Gastrointestinal cancer, Tumor M2-PK, Tumor marker, Cancer, Medicine, Pancreatic cancer, Colorectal cancer, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. — Research Paper | ScholarLens